What changed in this filing

/stocks — the workspaceLOADING

Item 1. Business

2026-03-30 compared with 2025-04-15 · 218 added, 198 removed, 528 unchanged (44% of the section changed)

11 unchanged sentences

continued to innovate by responding to the demand for and utilization of Real World Data (as defined below) (“RWD”) and Real

World Evidence (“RWE”), specifically data that focused on clinical images with its associated contextual clinical record.

We were able to leverage internal technological competencies along with OneMedNet’s formidable healthcare provider installed base

from its first product with BEAMTM to become the first RWD solution for life science companies with its launch of iRWDTM in 2019.

World Evidence (as defined below) (“RWE”), specifically data that focused on clinical images with its associated contextual

clinical record.

We were able to leverage internal technological competencies along with OneMedNet’s formidable healthcare provider

installed base from its first product with BEAMTM to become the first RWD solution for life science companies with its launch of iRWDTM

provides innovative solutions that unlock the significant value contained within clinical image archives.

3 unchanged sentences

The term “healthcare sites” refers specifically to the hospitals, integrated delivery networks

(“IDNs”) and imaging centers that provide imaging to OneMedNet, which represent the core source of our data.

OneMedNet has access to more than 1,400 sites who provide regulatory grade data to us.

and imaging centers that provide imaging to OneMedNet, which represent the core source of our data.

At present, OneMedNet has access

to more than 2,130 sites who provide regulatory grade data to us.

it was all about solving the diverse access needs of patient care providers.

32 unchanged sentences

and further gains from the image archives have been very limited.

help providers to “Unlock the Value in Imaging Archives.”TM By utilizing OneMedNet’s iRWDTM offering, providers can

greatly improve their research efforts with streamlined data access.

Health care providers such as hospitals, clinics, and imaging centers

can also accelerate life science patient care innovations by sharing de-identified data in a well-defined and de-identified and secure

In return for doing so, income is generated and applied to critical and possibly unfunded provider projects.

help providers to Unlock the Value in Imaging Archives.

By utilizing OneMedNet’s iRWDTM offering, providers can greatly improve

their research efforts with streamlined data access.

Health care providers such as hospitals, clinics, and imaging centers can also accelerate

life science patient care innovations by sharing de-identified data in a well-defined and de-identified and secure manner.

for doing so, income is generated and applied to critical and possibly unfunded provider projects.

OneMedNet Difference

2 unchanged sentences

specialized expertise in:

(HIPAA (as defined below), GDPR, 21 CFR Part11)

privacy & security measures

patient condition(s) and hospital processes

interpretation

(Artificial Intelligence and Machine Learning) technology

in-house expertise in all essential elements is a challenge and we believe deters many organizations from attempting such a venture.

Compliance (HIPAA (as defined

below), GDPR, 21 CFR Part11)

Advanced privacy &

security measures

Clinical patient condition(s)

and hospital processes

Radiology interpretation

Artificial Intelligence

and Machine Learning (“AI/ML”) technology

in-house expertise in all essential elements is a challenge and we believe it deters many organizations from attempting such a venture.

We take pride in this ambitious achievement while continually working to maintain state-of-the-art expertise.

1 unchanged sentence

to the highest level of professional and ethical standards and applicable regulations throughout all interactions and activities.

believe OneMedNet is a leader in the field of regulatory-grade imaging RWD curators.

believe OneMedNet is a leader in the field of regulatory-grade imaging RWD curation.

Doing so requires specialized expertise in AI/ML

14 unchanged sentences

Our in-house clinical team performs intensive curation of the data

so that results meet the specifications and requirements of life science Data Collection Protocol (“DCP”) - regardless of

the complexity.

so that results meet the specifications and requirements of life science Data Collection Protocol - regardless of the complexity.

believe that OneMedNet unlocks the value in imaging and EHR data in the following three principal ways:

Grade - Our imaging results serve as proof of effectiveness for regulatory agencies, meeting requirements for quality & diversity.

Demand - Our powerful indexing platform accesses and harmonizes complete patient profiles across fragmented data silos, delivering

images and records on-demand.

Curated - We curate to the most stringent multi-level stratified requirements, providing unmatched data accuracy and completeness.

Regulatory Grade - Our

imaging results serve as proof of effectiveness for regulatory agencies, meeting requirements for quality & diversity.

On Demand - Our powerful

indexing platform accesses and harmonizes complete patient profiles across fragmented data silos, delivering images and records on-demand.

Expertly Curated - We curate

to the most stringent multi-level stratified requirements, providing unmatched data accuracy and completeness.

data is fully de-identified using a multi-step quality control process and goes beyond protected health information (“PHI”)

5 unchanged sentences

Moreover, OneMedNet has the unique combination of knowledge, tools, and experience to:

and harmonize complete patient profiles across fragmented data silos;

unmatched data accuracy and completeness;

the security and privacy of patients’ PHI;

RWD is our singular passion and focus and no one does it better.

Access and harmonize complete

patient profiles across fragmented data silos;

Provide unmatched data

accuracy and completeness;

Ensure the security and

privacy of patients’ PHI;

Imaging RWD is our singular

passion and focus and no one does it better.

OneMedNet has a team of highly experienced and clinically trained data curators.

20 unchanged sentences

clinical trials, patient and provider surveys, wearable devices and more.

These additional sources include the internet of things (“IoT”),

social media forums and blogs.

Real World Data has the potential to break down inefficiencies and fill gaps in information silos among

stakeholders throughout the healthcare ecosystem of providers, payers, manufacturers, government entities and patients.

This information

sharing, in turn, enables all parties to derive new insights, support value-based care and deliver better health outcomes.

These additional sources include the internet of things, social

media forums and blogs.

Real World Data has the potential to break down inefficiencies and fill gaps in information silos among stakeholders

throughout the healthcare ecosystem of providers, payers, manufacturers, government entities and patients.

This information sharing,

in turn, enables all parties to derive new insights, support value-based care and deliver better health outcomes.

Commercializing

17 unchanged sentences

Here’s how it happens:

Real World Data are data relating to patient health status and/or the delivery of health care routinely collected from a variety

Real World Data is aggregated and transformed such as through OneMedNet’s robust analytics.

Real World Data are

the data relating to patient health status and/or the delivery of health care routinely collected from a variety of sources.

are many different types, sources and uses of Real World Data, for example:

Data - For example, clinical data from EHR and case report forms (“eCRF”) including biopsies and other pathology

tests, diagnostic imaging, social determinants of health, cancer organoids, which provide patient demographics, family history, comorbidities,

First, Real World Data

are data relating to patient health status and/or the delivery of health care routinely collected from a variety of sources.

World Data is aggregated and transformed, such as through OneMedNet’s robust analytics.

Real World Data are the data relating

to patient health status and/or the delivery of health care routinely collected from a variety of sources.

There are many different

types, sources and uses of Real World Data, for example:

Clinical Data -

For example, clinical data from EHR and case report forms (“eCRF”) including biopsies and other pathology tests,

diagnostic imaging, social determinants of health, cancer organoids, which provide patient demographics, family history, comorbidities,

procedure and treatment history, and outcomes.

Generated Data - For example, patient-generated data from patient-reported outcome surveys, which data provide insights directly

from the patient and help researchers understand what happens outside of clinic visits, procedures, and hospital stays.

and Utilization Data (Qualitative Studies) - For example, cost and utilization data from claims and public datasets,

which data provides information regarding healthcare services utilization, population coverage, and prescribing patterns.

Health Data - For example, public health data from various government data sources, which add critical information to enable

stakeholders to best serve the needs of the populations they serve.

Patient Generated Data

- For example, patient-generated data from patient-reported outcome surveys, which data provide insights directly from the patient

and help researchers understand what happens outside of clinic visits, procedures, and hospital stays.

Cost and Utilization

Data (Qualitative Studies) - For example, cost and utilization data from claims and public datasets, which data

provide information regarding healthcare services utilization, population coverage, and prescribing patterns.

Public Health Data

- For example, public health data from various government data sources, which add critical information to enable stakeholders

to best serve the needs of the populations they serve.

availability of medical imaging in Real World Data such as that provided by OneMedNet is facilitated by the development of digital image

14 unchanged sentences

When data and, in particular, imaging data is submitted to the FDA, the agency requires the following:

against bias - evidence must align with the patient population being studied - expectations focus on

the similar patient demographics, comorbidities, disease severity, etc.;

Guard against bias - evidence

must align with the patient population being studied - expectations focus on the similar patient demographics, comorbidities,

disease severity, etc.;

Traceability - confirm

the chain of custody, the source of the data is known and can be validated if required;

basis - regulatory agencies seek evidence that aligns with the trial’s timeframe and, when possible, collect

evidence that mirrors the clinical trial’s timeline.

Go-forward basis - regulatory

agencies seek evidence that aligns with the trial’s timeframe and, when possible, collect evidence that mirrors the clinical

trial’s timeline.

area where Real World Evidence has been relied on heavily relates to oncology approvals.

34 unchanged sentences

Real World Data and Real World Evidence, expanding end-to-end clinical trial capabilities:

ingestion - publicly/historically available Real World Data

extraction - NLP used to extract key entities from clinical trial documents

transformation & standardization - data standardization using pre-built models

model deployment - predicting trial design impacts on costs, feasibility, cycle times, and quality risk

Data ingestion - publicly/historically

available Real World Data

Text extraction - NLP

used to extract key entities from clinical trial documents

Data transformation &

standardization - data standardization using pre-built models

AI model deployment - predicting

trial design impacts on costs, feasibility, cycle times, and quality risk

is driving ground-breaking leaps in protein structure identification, and advances in regulations are providing healthcare research organizations

26 unchanged sentences

appropriate eligibility criteria.

Real World Evidence is the clinical evidence about the usage and potential benefits or risks of a medical product derived from analysis

of Real World Data.

Second, Real World Evidence

is the clinical evidence about the usage and potential benefits or risks of a medical product derived from analysis of Real World

Real World Evidence provides clinically-rich insights into what actually happens in everyday practice and why.

Federal Food, Drug, and Cosmetic Act of 1938 (“FD&C Act”) defines Real World Evidence as “ data

regarding the usage, or the potential benefits or risks, of a drug derived from sources other than traditional clinical trials.

In developing its Real World Evidence program, the FDA believes it is helpful to distinguish between the sources of Real World Data

and the evidence derived from that data.

Food, Drug, and Cosmetic Act of 1938 (“FD&C Act”) defines Real World Evidence as “ data regarding the usage,

or the potential benefits or risks, of a drug derived from sources other than traditional clinical trials.

” In developing

its Real World Evidence program, the FDA believes it is helpful to distinguish between the sources of Real World Data and the evidence

derived from that data.

Real World Evidence in the context of regulatory decision-making depends not only on the evaluation of the methodologies used to generate

3 unchanged sentences

Real World Evidence refers to evidence about the risks and benefits of a product derived from analysis of the Real

For example, the FDA has used Real World Data and Real World Evidence, derived from its Sentinel System, the largest multisite

For example, the FDA has used Real World Data and Real World Evidence, derived from its Sentinel System, the largest multi-site

distributed database in the world dedicated to medical product safety, for monitoring the safety of regulated products, in place of post-marketing

7 unchanged sentences

Real World Evidence is used by different stakeholders in many different ways.

gives life sciences companies insight into how their drugs are being used.

helps providers improve the delivery of care.

enables regulatory authorities to monitor post-market safety and adverse events.

helps payers assess outcomes from treatments.

It gives life sciences

companies insight into how their drugs are being used.

It helps providers improve

the delivery of care.

It enables regulatory authorities

to monitor post-market safety and adverse events.

It helps payers assess

outcomes from treatments.

Real World Data to Real World Evidence

4 unchanged sentences

steps, which are summarized here:

a study protocol answering relevant clinical questions.

which data elements can be collected from which Real World Data sources.

data capture arrangements and protocols with existing Real World Data sources.

disparate data sources through probabilistic record matching algorithms.

and supplementing blended data through editable eCRFs.

and calculating clinically relevant outcomes and measures.

Appropriately

assessing and controlling for variability in data quality, availability and confounding patient factors affecting measured outcomes.

World Evidence can provide a holistic view of patients that in many cases cannot be studied through traditional clinical trials.

Defining a study protocol

answering relevant clinical questions.

Defining which data elements

can be collected from which Real World Data sources.

Establishing data capture

arrangements and protocols with existing Real World Data sources.

Blending disparate data

sources through probabilistic record matching algorithms.

Validating and supplementing

blended data through editable eCRFs.

Defining and calculating

clinically relevant outcomes and measures.

Appropriately assessing

and controlling for variability in data quality, availability and confounding patient factors affecting measured outcomes.

Real World Evidence can

provide a holistic view of patients that in many cases cannot be studied through traditional clinical trials.

World Evidence has been proven to fill a gap between research (what we learn) and everyday practice (what we do) in healthcare, and it

71 unchanged sentences

they do have some limitations.

For example, a traditional clinical trial can have strict inclusion criteria that makes it challenging

For example, a traditional clinical trial can have strict inclusion criteria that make it challenging

for providers to accurately extrapolate the results of a clinical trial to a broader population.

83 unchanged sentences

Support from regulatory bodies

for using Real World Evidence solutions and an increase in research and development spending are anticipated to boost the market growth.

for using Real World Evidence solutions and an increase in research and development spending are anticipated to boost market growth.

Real World Evidence solution providers are increasingly forming strategic partnerships with AI solution providers to offer integrated

66 unchanged sentences

ONMD Canada’s functional currency is the Canadian dollar.

of Business Combination

November 7, 2023, following the approval of the Merger Agreement and the transactions contemplated thereby at the special meeting of

the shareholders of Data Knights held on October 17, 2023 (the “Special Meeting”), Merger Sub merged with and into Legacy

ONMD pursuant to the Merger Agreement (the “Merger”), with Legacy ONMD surviving the Merger as a wholly-owned subsidiary

of Data Knights.

Following Closing, Data Knights changed its name to “OneMedNet Corporation.”

Business Combination was accounted for as a reverse recapitalization in accordance with U.S.

generally accepted accounting principles

Under this method of accounting, Data Knights was treated as the acquired company and Legacy ONMD was treated as

the acquirer for financial statement reporting purposes.

Equity Purchase Agreement

June 17, 2024, we entered into a Standby Equity Purchase Agreement, or the SEPA, with Yorkville.

Under the SEPA, we have the right to

sell to Yorkville up to $25.0 million of our common stock, subject to certain limitations and conditions set forth in the SEPA, from

time to time, over a 24-month period.

Sales of our common stock to Yorkville under the SEPA, and the timing of any such sales, are at

our option, and we are under no obligation to sell any shares of our common stock to Yorkville under the SEPA except in connection with

notices that may be submitted by Yorkville, in certain circumstances as described below.

Upon the satisfaction of the conditions precedent

in the SEPA, which include having a resale shelf for shares of our common stock issued to Yorkville declared effective, we have the right

to direct Yorkville to purchase a specified number of shares of our common stock by delivering written notice.

Such purchase is referred

to as an “Advance.” An Advance may not exceed 100% of the average of the daily trading volume of our Class A common stock

on The Nasdaq Capital Market, or Nasdaq, during the five consecutive trading days immediately preceding the written notice.

will generally purchase shares of our common stock pursuant to an Advance at a price per share equal to 97% of the lowest daily volume

weighted average price, or VWAP, on Nasdaq during the three consecutive trading days commencing on the date of the delivery of the written

notice (unless we specify a minimum acceptable price or there is no VWAP on the subject trading day).

entry into the SEPA, we issued Yorkville a $1.5 million convertible promissory note for $1.35 million in cash (after a 10% original issue

discount), or the Initial Advance.

The note bears interest at an annual rate equal to 0.0% (increased to 18.0% in the event of default

as provided in the note) and matures June 17, 2025.

The note is convertible by Yorkville into shares of common stock at an aggregate

purchase price based on a price per share equal to the lower of (a) $1.3408 per share (subject to downward reset upon the filing of the

resale registration statement described below) or (b) 90% of the lowest daily volume-weighted average price (“VWAP”) of the

Common Stock on Nasdaq during the seven trading days immediately prior to each conversion (the “Variable Price”), but which

Variable Price may not be lower than the Floor Price then in effect.

The “Floor Price” is $0.28 per share, subject to the

Company’s option to reduce the Floor Price to any amounts set forth in a written notice to Yorkville.

Upon the occurrence and during

the continuation of an event of default (as defined in the note), the note will become immediately due and payable.

The issuance of our

common stock upon conversion of the note and otherwise under the SEPA is capped at 19.9% of our outstanding common stock as of June 17,

2024 in order to comply with applicable Nasdaq rules.

Further, the note and SEPA include a beneficial ownership blocker for Yorkville

such that Yorkville may not be deemed the beneficial owner of more than 4.99% of our common stock.

SEPA will automatically terminate on the earliest to occur of (i) the first day of the month next following the 24-month anniversary

of the date of the SEPA or (ii) the date on which Yorkville shall have made payment of for shares of our common stock equal to $25.0

We have the right to terminate the SEPA at no cost or penalty upon five trading days’ prior written notice to Yorkville,

provided that there are no outstanding advances for which shares of our common stock need to be issued and the convertible note (Initial

Advance) has been paid in full.

We and Yorkville may also agree to terminate the SEPA by mutual written consent.

As consideration for

Yorkville’s commitment to purchase the shares of our Class A common stock pursuant to the SEPA, we paid Yorkville a $25 thousand

cash structuring fee and a commitment fee equal to 526,312 shares of our common stock.

connection with the entry into the SEPA, on June 17, 2024, we entered into a registration rights agreement with Yorkville, pursuant to

which we agreed to file with the SEC no later than August 30, 2024, a registration statement for the resale by Yorkville of the shares

of our common stock issued under the SEPA (including the commitment fee shares).

We agreed to use commercially reasonable efforts to

have such registration statement declared effective within 30 days of such filing and to maintain the effectiveness of such registration

statement during the 24-month commitment period.

We will not have the ability to request any Advances under the SEPA (nor may Yorkville

convert the Initial Advance into our common stock) until such resale registration statement is declared effective by the SEC.

filing date of this Annual Report, we have not filed a registration statement with the SEC.

2024 Financings

July 23, 2024, we entered into a securities purchase agreement with Off the Chain Capital, LLC (“OTC”), pursuant to which

we agreed to issue and sell to OTC 1,297,059 shares of our Common Stock at a price of $1.0278 per

share and pre-funded warrants exercisable for 1,323,530 shares of our Common Stock at an exercise price of $1.0278 per share.

required to prepay the exercise price for the pre-funded warrants, other than $0.0001 per share.

The warrants and pre-funded warrants

will be exercisable at any time after the date of issuance and will not expire.

OTC is entitled to receive dividends on the pre-funded

2025 Financing

June 19, 2025, we entered into a securities purchase agreement with James Sixsmith (“Mr.

Sixsmith”), pursuant to which we

agreed to issue and sell to Mr.

Sixsmith 3,390,923 shares of our Common Stock at a price of $0.42 per share and pre-funded warrants exercisable

for 2,561,457 shares of our Common Stock at an exercise price of $0.42 per share.

was required to prepay the exercise price for the pre-funded warrants, other than $0.0001 per share.

The pre-funded warrants will be

exercisable at any time after the date of issuance and will not expire.

Sixsmith is entitled to receive dividends on the pre-funded

warrants, if declared, on an as-if-converted-to-common-stock basis, and in the same form as dividends actually paid on shares of our

Common Stock.

July 25, 2024, we entered into a securities purchase agreement with Discovery Capital Management, LLC (“Discovery”), pursuant

to which we agreed to issue and sell 2,301,791 shares of our Common Stock at a price of $0.85 per

received net proceeds of approximately $4.5 million from the July 2024 private placements, after deducting offering expenses of $0.1

2024 Financing

September 24, 2024, we entered into another securities purchase agreement with OTC, pursuant to

which we agreed to issue and sell to OTC 1,918,591 shares of our Common Stock at a price of $0.65 per share, warrants exercisable for

133,095 shares of our Common Stock at an exercise price of $0.325 per share, and pre-funded warrants exercisable for 743,314 shares of

our Common Stock at an exercise price of $0.65 per share.

OTC was required to prepay the exercise price for the pre-funded warrants,

other than $0.0001 per share.

The warrants and pre-funded warrants will be exercisable at any time after the date of issuance and will

OTC is entitled to receive dividends on the pre-funded warrants, if declared, on an as-if-converted-to-common-stock

basis, and in the same form as dividends actually paid on shares of our Common Stock.

received net proceeds of approximately $1.7 million, after deducting an immaterial amount of offering expenses.

We have not yet issued

the 1,918,591 shares of our Common Stock in order to keep OTC’s ownership percentage below a defined threshold.

received net proceeds of $2.5 million from the June 2025 private placement, after deducting an immaterial amount of offering expenses.

Agreements – Related Parties

June 20, 2025, we entered into subscription agreements with Dr.

Thomas Kosasa and Dr.

Jeffrey Yu, pursuant to which we agreed to issue

1,190,476 and 1,666,667 shares of our Common Stock, respectively, at a price of $0.42 per share.

August 29, 2025, we entered into another subscription agreements with Dr.

Thomas Kosasa, pursuant to which we agreed to issue 581,395

shares of our Common Stock, at a price of $0.86 per share.

received net proceeds of approximately $1.7 million from these subscription agreements, after deducting an immaterial amount of offering

June 17, 2025 and June 19, 2025, the holders of Pre-Closing PIPE Notes delivered notices to the Company of their respective elections

to convert an aggregate of $1.7 million of outstanding principal and accrued interest (carrying amount of $0.5 million at the time of

conversion) under the PIPE Notes (the “PIPE Notes Conversion”).

Under the PIPE Notes Conversion, we issued an aggregate of

1,453,174 shares of Common Stock in full satisfaction of the PIPE Notes.

The PIPE Notes were converted pursuant to their terms at a conversion

price of $1.14 per share.

June and July 2025, we negotiated and settled certain trade payables and other amounts owed by the Company representing an aggregate

of approximately $6.3 million of current liabilities as reflected on the Company’s consolidated balance sheets as of December 31,

2024, which amount includes the settlement of approximately $3.3 million of deferred underwriter fees payable to EF Hutton (the “Settlements”).

entered into a letter agreement, dated May 19, 2025, with Slickage (the “Slickage Agreement”) to settle $177,500 of trade

accounts payable owed by the Company to Slickage through the issuance of 250,000 shares of Common Stock to Slickage (the “Slickage

Shares”), representing a conversion price of $0.71 per share.

Pursuant to the Slickage Agreement, we agreed to register for resale

the Slickage Shares on our registration statement declared effective by the SEC on July 24, 2025.

June 19, 2025, we entered into agreements with Dr.

Kosasa and Dr.

Yu to convert an aggregate of approximately $3.3 million of outstanding

principal and accrued interest under certain shareholder loans and business combination extension loans (collectively, the “Loans”)

Kosasa and Dr.

Yu to the Company into an aggregate of 4,693,299 shares of Common Stock (the “Loan Conversions”).

The Loans were converted at a conversion price of $0.71 per share.

Pursuant to Loan Conversions, (i) Dr.

Kosasa converted Loans with

aggregate principal and accrued interest of approximately $3.6 million for 2,865,019 shares of Common Stock, and (ii) Dr.

Loans with aggregate principal and accrued interest of approximately $1.3 million for 1,828,280 shares of Common Stock.

The shares of

Common Stock issued under the Loan Conversions were issued in reliance on the exemptions from registration provided by Section 4(a)(2)

under the Securities Act.

June 19, 2025, Dr.

Kosasa delivered notice to the Company of his election to convert in full the amounts of outstanding principal under

certain convertible shareholder loans (the “Kosasa Convertible Loans”) previously made by Dr.

Kosasa to the Company, in an

aggregate principal amount of approximately $1.6 million, converting into an aggregate of 2,123,424 shares of Common Stock (the “Kosasa

Convertible Loan Conversions”).

The Kosasa Convertible Loans were converted pursuant to their terms at a conversion price of $0.7535

The shares of Common Stock delivered to Dr.

Kosasa upon the Kosasa Convertible Loan Conversions were delivered in full satisfaction

of amounts owed to Dr.

Kosasa under the Kosasa Convertible Loans.

between May and July of 2025, as reflected above, the Company settled or converted an aggregate of approximately $11.9 million of current

liabilities of the Company in connection with the Settlements, the Loan Conversions, the Kosasa Convertible Loan Conversions and the

PIPE Notes Conversions, representing a 62% reduction in the Company’s total liabilities outstanding as of December 31, 2025.

aspects of our businesses are regulated by federal and state laws, rules and regulations.

21 unchanged sentences

prosecution, including corporate fines and personal liability.

of our operations are subject to regulation under the administrative simplification provisions of the Health Insurance Portability and

Accountability Act of 1996, as amended (“HIPAA”).

Federal regulations related to HIPAA contain minimum standards for electronic

transactions and code sets and for the privacy and security of protected health information.

Patient health information is among the

most sensitive of personal information, and it is critically important that information about an individual’s healthcare is properly

protected from inappropriate access, use and disclosure.

Real World Evidence - information that allows us to examine actual

practices and outcomes - is essential to increase access to care, improve outcomes, and lower costs.

of our operations are subject to regulation under the administrative simplification provisions of HIPAA.

Federal regulations related

to HIPAA contain minimum standards for electronic transactions and code sets and for the privacy and security of protected health information.

Patient health information is among the most sensitive of personal information, and it is critically important that information about

an individual’s healthcare is properly protected from inappropriate access, use and disclosure.

Real World Evidence - information

that allows us to examine actual practices and outcomes - is essential to increase access to care, improve outcomes, and

uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information

2 unchanged sentences

We employ a wide variety of methods to manage privacy requirements, including:

frameworks, models and training to promote good decision making and accountability;

layered approach to privacy and security management to avoid a single point of failure;

evaluation of privacy and security practices to promote continuous improvement;

of technical, administrative, physical and organizational safeguards and controls;

collaboration

with data suppliers and trusted third parties for our syndicated market research and analytics offerings to remove identifiable information

governance, frameworks,

models and training to promote good decision making and accountability;

a layered approach to privacy

and security management to avoid a single point of failure;

ongoing evaluation of privacy

and security practices to promote continuous improvement;

use of technical, administrative,

physical and organizational safeguards and controls;

collaboration with data

suppliers and trusted third parties for our syndicated market research and analytics offerings to remove identifiable information

or employ effective encryption or other techniques to render information non-identified before data is delivered to us;

with leading researchers, policy makers, thought leaders and others in a variety of fields relevant to the application of effective

privacy and security practices, including statistical, epidemiological and cryptographic sciences, legal, information security and

compliance, and privacy.

work with leading researchers,

policy makers, thought leaders and others in a variety of fields relevant to the application of effective privacy and security practices,

including statistical, epidemiological and cryptographic sciences, legal, information security and compliance, and privacy.

have relied on expertise in the industry with de-identifying data.

15 unchanged sentences

so that privacy requirements are addressed in technology, contracting, offerings and other business activities.

OneMedNet Privacy Policy (the “Privacy Policy”) is our foundational privacy policy.

It explains how, when applicable, we

collect, hold, use and disclose personal information, including that of our personnel, consumers, healthcare professionals, patients,

medical research subjects, clinical investigators, customers, suppliers, vendors, business partners and investors.

OneMedNet Privacy Policy is our foundational privacy policy.

It explains how, when applicable, we collect, hold, use and disclose personal

information, including that of our personnel, consumers, healthcare professionals, patients, medical research subjects, clinical investigators,

customers, suppliers, vendors, business partners and investors.

Quality Compliance (FDA 21 CFR Part 11)

6 unchanged sentences

This program includes:

internal audits, policy reviews, and procedure testing to ensure validation, audit trails, legacy systems, and record handling and

retention adhere to the latest regulatory guidelines and best practices;

third-party or client-initiated external audits to assess the compliance of OneMedNet to ensure operations are in accordance with

the applicable regulations, standards, policies, and standard operating procedures.

Ongoing internal audits,

policy reviews, and procedure testing to ensure validation, audit trails, legacy systems, and record handling and retention adhere

to the latest regulatory guidelines and best practices;

Regular third-party or

client-initiated external audits to assess the compliance of OneMedNet to ensure operations are in accordance with the applicable

regulations, standards, policies, and standard operating procedures.

Capital Resources

9 unchanged sentences

a company with less than $1.235 billion in revenues during our last fiscal year, we qualify as an emerging growth company as defined

in the Jumpstart Our Business Startups Act (“JOBS Act”) enacted in 2012.

As an emerging growth company, we expect to take

advantage of reduced reporting requirements that are otherwise applicable to public companies.

These provisions include, but are not

being permitted to present only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced “Management’s Discussion and Analysis of Financial Condition and Results of Operations” disclosure;

not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended (“Sarbanes-Oxley Act”);

reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements;

from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute

payments not previously approved.

JOBS Act enacted in 2012.

As an emerging growth company, we expect to take advantage of reduced reporting requirements that are otherwise

applicable to public companies.

These provisions include, but are not limited to:

being permitted to present

only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly

reduced “Management’s Discussion and Analysis of Financial Condition and Results of Operations” disclosure;

not being required to comply

with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended (“Sarbanes-Oxley Act”);

reduced disclosure obligations

regarding executive compensation in our periodic reports, proxy statements and registration statements;

exemptions from the requirements

of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously

file with, or furnish to, the SEC reports, including our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports

8 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 1. Business